Is Tevogen Bio Holdings Inc. (TVGN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 9.8% / 30% | 4.3% / 30% | 0.5% / 30% | N/A | ✓ HALAL |
| DJIM | 9.8% / 33% | 4.3% / 33% | 0.5% / 33% | N/A | ✓ HALAL |
| MSCI | 83.4% / 33% | 37.1% / 33% | 4.6% / 33% | N/A | ✗ NOT HALAL |
| S&P | 9.8% / 33% | 4.3% / 33% | 0.5% / 33% | N/A | ✓ HALAL |
| FTSE | 83.4% / 33% | 37.1% / 33% | 4.6% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -439.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$12M |
| Free Cash Flow | -$12M |
| Total Debt | $3M |
| Current Ratio | 0.3 |
| Total Assets | $3M |
Price & Trading
| Last Close | $4.76 |
| 50-Day MA | $11.58 |
| 200-Day MA | $31.73 |
| Avg Volume | 25K |
| Beta | -0.7 |
|
52-Week Range
$4.18
| |
About Tevogen Bio Holdings Inc. (TVGN)
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Tevogen Bio Holdings Inc. (TVGN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Tevogen Bio Holdings Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Tevogen Bio Holdings Inc.'s debt ratio?
Tevogen Bio Holdings Inc.'s debt ratio is 9.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 83.4%.
What are Tevogen Bio Holdings Inc.'s key financial metrics?
Tevogen Bio Holdings Inc. has a market capitalization of $18M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.